Jinxin Fertility Group Limited provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expects that the net profit will increase by no less than 192% compared to that of the Group for the year ended December 31, 2022. Such increase was primarily attributable to (i) the recovery and growth experienced by the Group across its assisted reproductive medical facilities after the cessation of the COVID-19 pandemic, including an increase in the number of patient visits and in vitro fertilization (IVF) treatment cycles; and (ii) the optimizing and strengthening of the operational efficiency of the Group and its medical facilities.